Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53

Ido Goldstein1, Noa Rivlin, Or-yam Shoshana

  • 1The Department of Molecular Cell Biology, the Weizmann Institute of Science, Rehovot, 76100 Israel. Ido.goldshtein@weizmann.ac.il

Carcinogenesis
|October 12, 2012
PubMed

Insights

The tumor suppressor p53 (a protein) activates liver P450 enzymes, impacting drug metabolism. This discovery reveals a new role for p53 in how the liver processes substances, crucial for chemotherapy design.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Cytochrome P450 (P450) enzymes are crucial for metabolizing organic substrates, primarily in the liver.
  • The p53 protein is a well-known tumor suppressor involved in cellular responses to DNA damage.

Purpose of the Study:

  • To investigate the role of p53 in regulating the expression of P450 genes in human liver cells.
  • To characterize the mechanism of p53-mediated induction of specific P450 genes.

Main Methods:

  • Microarray screening of P450 gene expression in human liver cells.
  • p53-dependent gene induction studies in liver cell lines and primary human hepatocytes.
  • Analysis of p53 binding to DNA regulatory regions and reporter gene assays.
  • Assessment of P450 enzyme activity following p53 activation by chemotherapeutic agents.

Main Results:

  • Eleven P450 genes were found to be induced by p53 in human liver cells.
  • p53 directly binds to regulatory elements and enhances transcription of P450 genes.
  • Activation of p53 by chemotherapy (cisplatin, etoposide, doxorubicin) induced CYP3A genes, enhancing P450 activity.

Conclusions:

  • Hepatic p53 plays a novel role in inducing P450 enzymes, influencing the response to xenobiotics and metabolic signals.
  • This p53-mediated induction of CYP3A enzymes by their substrates necessitates careful consideration in chemotherapy regimen design.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...